American pharmaceutical and biotechnology company, Moderna, seeks to invest over $500-million in a vaccine and drug manufacturing facility in Kenya. President Uhuru Kenyatta attended a signing ceremony of a Memorandum of Understanding (MoU) between Kenya and Moderna in Nairobi. The new facility will help solve the problem of vaccine inequity experienced across Africa, which has not received its fair share of COVID-19 vaccines. Kenyatta stated that the challenges are the lack of vaccines that Kenya could purchase. The Messenger RNA (mRNA) facility, which will focus on drug substance manufacturing, is expected to produce up to 500 million doses of vaccines each year. Moderna’s Chief Executive Officer Stephane Bancel has stated that his company is committed to partnering to provide a health solution, and investment the company is making in Kenya is essential, as it is part of the solution to ensuring global health equity. – 2022©️Willshir & Associates – Business Intelligence Program